- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Non-small cell lung cancer (NSCLC)
- Meeting Date: November 2021
- Public Summary Document (PSD) November 2021 PBAC Meeting - (PDF 2107KB)
- Public Summary Document (PSD) November 2021 PBAC Meeting - (Word 1268KB)
Tepotinib – November 2021
Tepotinib: Tablet 225 mg (as hydrochloride monohydrate); Tepmetko®
Last updated
18 March 2022